Showing results (1731-1740 of 3,592) with videos related to
Sort By:
Pageof 360
Journal of Viral Hepatitis|July 1, 1997
Antibody to hepatitis E virus in HIV-infected individuals and AIDS patientsM S Balayan, O E Fedorova, M I Mikhailov, et al.Journal of Viral Hepatitis|May 8, 1998
Medical practices regarding hepatitis C virus infection in EuropeB Nalpas, E Delaroques-Astagneau, C L Bihan, et al.Journal of Viral Hepatitis|January 1, 1997
Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmissionJ D Spencer, N Latt, P J Beeby, et al.Journal of Viral Hepatitis|January 1, 1997
Concordance between hepatitis C virus serotyping assaysR G Gish, K P Qian, S Quan, et al.Journal of Viral Hepatitis|February 22, 2023
The infection rates of HBV and HCV decreased significantly in Zhejiang Province, China: A comparative study based on the data of two sero-epidemiological surveys in 1992 and 2020Yang Zhou, Botao Zhao, Wen Shi, et al.Journal of Viral Hepatitis|March 9, 2023
Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological responseLixia Qiu, Shanshan Xu, Yundong Qiu, et al.Journal of Viral Hepatitis|August 2, 2016
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative studyH Nishikawa, H Enomoto, Y Iwata, et al.Journal of Viral Hepatitis|July 3, 2015
Clinical impact of treatment timing for chronic hepatitis C infection: a decision modelM T Pho, D M Jensen, D O Meltzer, et al.Journal of Viral Hepatitis|August 26, 2021
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis BHye Won Lee, Young Youn Cho, Hyein Lee, et al.Journal of Viral Hepatitis|August 27, 2021
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trialsEdward Gane, Victor de Ledinghen, Douglas E Dylla, et al.Pageof 360